Table 2.
Demographic and clinical data of women—participants in placebo-controlled trial on the clinical efficacy, oxidative markers, and TNF-alpha ligand levels of fermented mangosteen (FM) supplementation.
| Group | Number of Subjects | Age Range |
|---|---|---|
| HPV16, HPV18, no dysplasia Group 1—placebo Group 2—fermented mangosteen (FM) |
152 70 82 |
25–45 year |
| HPV16, HPV18, CIN I + CIN II Group 3—placebo Group 4—fermented mangosteen (FM) |
98 48 50 |
25–52 year |
| Healthy controls without viral infections | 30 | 27–42 year |